Journals / Güncel Retina Dergisi / 2017 / Cilt: 1 - Sayı: 3

Stem Cell and Gene Therapy For Wet-Form (Neovascular) Age-Related Macular Degeneration

Yaş Tip (Neovasküler) Yaşa Bağlı Maküla Dejenerasyonunda Kök Hücre ve Gen Tedavisi

Pages
241–245
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Nowadays there are ongoing or finished trials which give a hope for the treatment of this disease

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Treatment of wet-form (neovascular) Age-Related Macular Degeneration is nowadays based on recurrent intravitreal injections of anti-vascular endothelial growth factors.
📊
Key Findings & Data:But this treatment does not cure the patients or does not cause complete resolution of the disease.
💡
Conclusion & Impact:Nowadays there are ongoing or finished trials which give a hope for the treatment of this disease
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Treatment of wet-form (neovascular) Age-Related Macular Degeneration is nowadays based on recurrent intravitreal injections of anti-vascular endothelial growth factors. But this treatment does not cure the patients or does not cause complete resolution of the disease. So there is a need of other treatment modalities such as stem cell or gene therapies. Nowadays there are ongoing or finished trials which give a hope for the treatment of this disease

Özet

Yaş tip (neovasküler) Yaşa Bağlı Maküla Dejenerasyonu (YBMD) tedavisinde günümüzde intravitreal anti vasküler endotelyal büyüme faktörü (anti-VEGF) enjeksiyonları uygulanmaktadır. Fakat bu enjeksiyonlar sadece hastalığın süpresyonunu sağlamakta ve kesin tedavi oluşturmamaktadır. Ayrıca bu tedavilerin pahalı oluşu ve enjeksiyonların sık aralıklarla yapılması gerekliliği tedavide aksamalara neden olmaktadır. Bu nedenlerden dolayı yaş tip YBMD tedavisinde kök hücre ve gen tedavilerini gündeme gelmiştir. Günümüzde devam eden ve bitmiş kök hücre ve gen tedavi çalışmaları umut vericidir

🔖

Cite This Article

BEYAZYILDIZ, E., KOÇAK, N. (2017). Stem Cell and Gene Therapy For Wet-Form (Neovascular) Age-Related Macular Degeneration. Güncel Retina Dergisi, Cilt: 1 - Sayı: 3, 241–245. https://ajindex.com/articles/198377

References (1)

  1. Akkoyun İ Yaşa Bağlı Maküla Dejenerasyonu Sınıflandırma ve Patogenez Turk J Ophthalmol 2014; 44:476-80 2. Owen C, Jarrar Z, Wormald R, Cook D, Fletcher A, Rudnicka A.The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012;96:752–756. 3. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVENUP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–2299. 4. Loeffler M, Roeder I. Tissue stem cells: definition, plasticity, heterogeneity, self-organization and models--a conceptual approach. Cells Tissues Organs 2002;171(1):8-26 5. Alpaslan Pınarlı F. Sıcan kemik iliği mezenkimal kok hucrelerinin insan amnion membranı ile kornea yanık tedavisinde kullanımı (Doktora Tezi). Ondokuz Mayıs Universitesi Sağlık Bilimleri Enstitusu Tıbbi Biyoloji Anabilim Dalı, Samsun, 2009 6. Tropepe V., Coles B.L., Chiasson B.J., Horsford D.J., Elia A.J., McInnes R.R., van der Kooy D. Retinal stem cells in the adult mammalian eye. Science, 2000 287, 2032–36. 7. Acar U. Kuru Tip (Non-Neovaskuler) Yaşa Bağlı Maküla Dejenerasyonunda Kok Hucre Tedavisi, Gen Tedavisi ve Retinal İmplant. Guncel Retina 2017;1(2):149-154 8. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embriyos. Nature 1981; 292: 154–56. 9. Lanza R, Gearhart J, Hogan B, et al, eds. Essentials of stem cell biology, 2nd edn. San Diego: Academic Press/Elsevier, 2009. 10. Kaplan HJ, Tezel TH, Berger AS, Del Priore LV. Retinal transplantation. In: Streilein JW, ed. Immune response and the eye. Chem Immunol. Basel: Karger, 1999: 207–19. 11. Lund RD, Wang S, Klimanskaya I, et al. Human embriyonic stem cell-derived cells rescue visual function in dystrophic rats. Cloning Stem Cells 2006; 8: 189–99. 12. Carr A.-J. F, Smart M. J. K, Ramsden C. M, Powner M. B, da Cruz L. and Coffey P. J. Development of human embriyonic stem cell therapies for age-related macular degeneration. Trends Neurosci. 2013; 36, 385-395 10.1016/j. tins.2013.03.006 13. Lu B, Malcuit C, Wang S, et al. (2009). Long-term safety and function of RPE from human embriyonic stem cells in preclinical models of macular degeneration. Stem Cells 2009; 27, 2126-35 14. Carr A.-J, Vugler A. A, Hikita S. T et al. Protective effects of human iPS-derived retinal pigment epithelium cell transplantation in the retinal dystrophic rat. PLoS ONE 2009; 4, e8152 10.1371/jour